Hologic, Inc. is a global medical technology company with a market cap of $16.7 billion, focusing on women’s health through diagnostic products and surgical solutions. Analysts expect HOLX to report an adjusted EPS of $1.09 for fiscal Q1 2026, a 5.8% increase from the previous year.

For fiscal 2026, analysts predict Hologic to post an adjusted EPS of $4.50, a 5.6% rise from fiscal 2025. Looking ahead to fiscal 2027, adjusted EPS is expected to grow by 10.2% year-over-year to $4.96.

HOLX stock has risen 3.1% over the past 52 weeks, underperforming the S&P 500 Index and State Street Health Care Select Sector SPDR ETF. Following its Q4 2025 results, Hologic’s stock rose marginally as the company reported strong growth in revenue and adjusted EPS.

Analysts have a cautious consensus rating on HOLX stock, with one “Strong Buy” and 17 “Hold” ratings. The average analyst price target for Hologic is $76.85, suggesting a potential upside of 2.5% from current levels.

Read more at Yahoo Finance: What You Need To Know Ahead of Hologic’s Earnings Release